Gaya Herald

Dry Age Macular Degeneration Pipeline Insight Report | 40+ Companies and 40+ Therapies

 Breaking News
  • No posts were found

Dry Age Macular Degeneration Pipeline Insight Report | 40+ Companies and 40+ Therapies

January 17
16:56 2023
Dry Age Macular Degeneration Pipeline Insight Report | 40+ Companies and 40+ Therapies

DelveInsight’s, “Dry Age-Related Macular Degeneration Pipeline Insight 2023,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in the Dry Age-Related Macular Degeneration pipeline landscape. It covers the Dry Age-Related Macular Degeneration pipeline drug profiles, including Dry Age-Related Macular Degeneration clinical trial and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

“For patients with advanced Dry Age-Related Macular Degeneration, also called geographic atrophy (GA), there is currently no FDA-approved therapy. There are, however, several treatments that are currently in clinical trials. Apl-2, Zimura, Oracea, and others are the drug molecules recently being investigated for the treatment of late-stage dry AMD. Strong Dry Age-related Macular Degeneration pipeline is anticipated to augment the market.”

 

Key takeaways from the Dry Age Macular Degeneration Pipeline Report

  • DelveInsight’s Dry Age-related Macular Degeneration Pipeline analysis depicts a robust space with 40+ active players working to develop 40+ pipeline therapies.
  • Some of the key pharmaceutical players working to develop potential drug candidates to improve the Dry Age-related Macular Degeneration treatment landscape include Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix, and others.
  • Key Dry Age-related Macular Degeneration pipeline therapies in various stages of development include ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011,  4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics, and others.
  • The Dry Age-related Macular Degeneration Companies and academics are working to assess challenges and seek opportunities that could influence Dry Age-Related Macular Degeneration R&D. The Dry Age-related Macular Degeneration pipeline therapies under development are focused on novel approaches to treat/improve Dry Age-Related Macular Degeneration.

 

Discover more about the Dry Age-related Macular Degeneration Pipeline Report offerings @ Dry Age-related Macular Degeneration Pipeline Outlook

 

Recent Developmental Activities in the Dry Age-related Macular Degeneration Treatment Landscape

  • In July 2021, IVERIC bio announced the early completion of patient enrollment in GATHER2, the Company’s second pivotal clinical trial of Zimura® (avacincaptad pegol) in development for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
  • In June 2021, Ocular Therapeutix and Mosaic Biosciences entered into strategic discovery collaboration targeting the treatment of dry age-related macular degeneration. Under the terms of the agreement, Ocular Therapeutix has agreed to fund the research performed under the collaboration and retains all program inventions and associated intellectual property.
  • The US Food and Drug Administration (FDA) has granted Fast Track designation to Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
  • In January 2021 Gemini Therapeutics announced that GEM103, the company’s investigational treatment for dry AMD, had been granted Fast Track designation by the FDA.
  • In September 2020, the US FDA had granted Fast Track designation to GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
  • In December 2020, Janssen Pharmaceuticals announced the acquisition of rights to Hemera Biosciences, LLC’s investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD).
  • On January 13, 2022, ONL Therapeutics, announced that it has closed on its second tranche of the Company’s Series B financing. The total proceeds raised in the Series B was $46.9 million upon Achieving ONL1204 Development Milestones. The company is advancing ONL1204 into open-angle glaucoma and GA associated with dry AMD.

 

Dry Age-related Macular Degeneration Overview

Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. “Age-related” means that it mainly occurs with elderly adults, while “Macular” means that the macula part of the eye is damaged. AMD mostly affects people aged above 50, and it was first reported more than 80 years ago. Dry macular degeneration is a common eye disorder among people aged above 50 years. It causes blurred or reduced central vision due to thinning of the macula.

 

Find out more about the Dry Age-related Macular Degeneration Recent Developments @ Dry Age-related Macular Degeneration Clinical Trials Analysis

 

Dry Age-Related Macular Degeneration Emerging Drugs Profile

 

 ALK-001: Alkeus Pharmaceuticals

ALK-001 is once-a-day oral drug candidate currently being tested in Phase III clinical trial for the treatment of geographic atrophy (advanced form of AMD) and Stargardt disease. Toxic vitamin A aggregates called “”dimers”” are known to rapidly form due to a genetic defect in Stargardt, or to accumulate with age in the case of dry AMD. These toxic dimers have been implicated in the degeneration of the retina seen in Stargardt and AMD. Dimers form when two molecules of vitamin A are chemically combined. ALK-001 is form of vitamin A that has been chemically-modified to prevent its aggregation into dimers. 

 

Zimura: Iveric bio

Zimura (avacincaptad pegol) is an investigational drug product designed to target and inhibit the cleavage of complement protein C5 and the formation of its downstream fragments, C5a and C5b. By inhibiting the formation of these fragments, Zimura is believed to decrease or slow the chronic inflammation and cell death associated with the retinal aging process by decreasing the formation of membrane attack complex (MAC) and inflammasome activity, thereby potentially avoiding or slowing the degeneration of retinal pigment epithelial cells. 

 

Visomitin: Mitotech

Visomitin is an eye drop formulation of SkQ1 that has been developed to target ophthalmic disorders like dry eye syndrome, uveitis and age-related macular degeneration. SkQ1 – is a purposely designed cardiolipin peroxidation inhibitor. SkQ1 was developed to deliver a highly active antioxidant plastoquinone into mitochondria. Once positioned in mitochondria, the molecule acts as a mitochondria-targeted ROS scavenger in general and as a very efficient cardiolipin protector in particular. 

 

Risuteganib: Allegro Ophthalmics

Risuteganib is an investigational integrin-regulating therapy that is believed to reduce mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, risuteganib may help reduce the cellular burden of oxidative stress and restore retinal homeostasis. Two concurrent Phase 3 studies evaluating the use of intravitreal risuteganib to treat intermediate dry AMD are expected to begin within the next 12 months. A Phase II clinical trial evaluating risuteganib in Dry AMD has been completed by allegro Ophthalmics. 

 

GT005: Gyroscope Therapeutics

Gyroscope’s lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. An overactive complement system has been implicated in the development of AMD. GT005 is designed to restore balance to an overactive complement system, a part of the immune system, by increasing production of the CFI protein. The CFI protein regulates the activity of the complement system. It is believed that increasing CFI production will dampen the systems over activity and reduce inflammation, with the goal of preserving a person’s eyesight. Gyroscope’s lead candidate, GT005, is currently in two Phase IIs for patients with geographic atrophy, an irreversible degeneration of retinal cells caused by dry-AMD. 

 

GEM103: Gemini Therapeutics

Gemini’s lead program, GEM103, is a pioneering precision medicine approach, targeting trial enrichment with genetically-defined patients. GEM103 targets a genetically-defined subset of age-related macular degeneration (AMD) patients with complement dysregulation. GEM103 is believed to be the first ever recombinant native complement modulator, full-length recombinant complement factor H (rCFH) protein. When delivered by intravitreal injection, GEM103 has the potential to address unmet medical need in genetically-defined subsets of AMD patients by circumventing dysfunctional CFH loss-of-function variants and slowing the progression of their retinal disease. A Phase II clinical trial is currently being evaluated to treat patients with Dry AMD and other retinal disease.

 

Dry Age-Related Macular Degeneration Therapeutic Assessment

There are approx. 40+ key companies which are developing the therapies for Dry Age-Related Macular Degeneration. The companies which have their Dry Age-Related Macular Degeneration drug candidates in the most advanced stage, i.e. Phase III include, Alkeus Pharmaceuticals.

 

Learn more about the novel and emerging Dry Age-related Macular Degeneration pipeline therapies @ Dry Age-related Macular Degeneration Treatment Landscape

 

Dry Age-related Macular Degeneration Segmentation Assessment

The Dry Age-related Macular Degeneration Pipeline report proffers an integral view of the Dry Age-related Macular Degeneration emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

 

Scope of the Dry Age-related Macular Degeneration Pipeline Report

  • Coverage- Global
  • Companies- Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix, and others
  • Pipeline Therapies- ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011,  4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics, and others.
  • Dry Age-related Macular Degeneration Segmentation: Product Type, Mechanism of Action, Route of Administration, Molecule Type

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Dry Age-Related Macular Degeneration: Overview
  4. Dry Age-Related Macular Degeneration Pipeline Therapeutics
  5. Dry Age-Related Macular Degeneration Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. ALK-001: Alkeus Pharmaceuticals
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Visomitin: Mitotech
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I/II)
  13. RPESC-RPE-4W: Luxa Biotechnology
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Dry Age-Related Macular Degeneration Key Companies
  17. Dry Age-Related Macular Degeneration Key Products
  18. Dry Age-Related Macular Degeneration- Unmet Needs
  19. Dry Age-Related Macular Degeneration- Market Drivers and Barriers
  20. Dry Age-Related Macular Degeneration- Future Perspectives and Conclusion
  21. Dry Age-Related Macular Degeneration Analyst Views
  22. Dry Age-Related Macular Degeneration Key Companies
  23. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Dry Age-Related Macular Degeneration drugs?
  • How many Dry Age-Related Macular Degeneration drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dry Age-Related Macular Degeneration?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dry Age-Related Macular Degeneration therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Dry Age-Related Macular Degeneration and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/